Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 8, Pages 1197-1205
Publisher
Informa Healthcare
Online
2013-07-02
DOI
10.1517/14712598.2013.812629
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
- (2013) Ghassan Dbaibo et al. DRUGS & AGING
- Acquisition of Meningococcal Serogroup W-135 Carriage in Turkish Hajj Pilgrims Who Had Received the Quadrivalent Meningococcal Polysaccharide Vaccine
- (2012) M. Ceyhan et al. Clinical and Vaccine Immunology
- Impact of the 7-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Younger Than 90 Days in England and Wales
- (2012) S. N. Ladhani et al. CLINICAL INFECTIOUS DISEASES
- Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
- (2012) Paul A. Kristiansen, Fabien Diomandé, Absatou Ky Ba, Idrissa Sanou, Abdoul–Salam Ouédraogo, Rasmata Ouédraogo, Lassana Sangaré, Denis Kandolo, Flavien Aké, Inger Marie Saga, Thomas A. Clark, Lara Misegades, Stacey W. Martin, Jennifer Dolan Thomas, Sylvestre R. Tiendrebeogo, Musa Hassan-King, Mamoudou H. Djingarey, Nancy E. Messonnier, Marie-Pierre Préziosi, F. Marc LaForce, Dominique A. Caugant CLINICAL INFECTIOUS DISEASES
- Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)
- (2012) Jamie D. Croxtall et al. DRUGS
- The dynamic and changing epidemiology of meningococcal disease at the country-based level: the experience in Turkey
- (2012) Ener Cagri Dinleyici et al. Expert Review of Vaccines
- MenACWY-TT vaccine for active immunization against invasive meningococcal disease
- (2012) Vassiliki Papaevangelou et al. Expert Review of Vaccines
- The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
- (2012) Ghassan Dbaibo et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
- (2012) Lars Østergaard et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: A cost-effectiveness analysis
- (2012) David Bin Chia Wu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers
- (2012) Guillermo M. Ruiz-Palacios et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
- (2012) Mari Rose Aplasca-De Los Reyes et al. Human Vaccines & Immunotherapeutics
- Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
- (2012) Timo Vesikari et al. Human Vaccines & Immunotherapeutics
- Increase of meningococcal serogroup Y cases in Europe: A reason for concern?
- (2012) Michael Bröker et al. Human Vaccines & Immunotherapeutics
- Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
- (2012) Markus Knuf et al. Human Vaccines & Immunotherapeutics
- The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine
- (2012) Ghassan Dbaibo et al. Human Vaccines & Immunotherapeutics
- Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
- (2011) Nancy Bermal et al. Human vaccines & immunotherapeutics
- Bacterial Meningitis in the United States, 1998–2007
- (2011) Michael C. Thigpen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile
- (2011) Ziad A. Memish et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
- (2011) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
- (2011) Markus Knuf et al. VACCINE
- Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial
- (2011) Timo Vesikari et al. VACCINE
- A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial
- (2011) Lars Østergaard et al. VACCINE
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
- (2010) H. Campbell et al. Clinical and Vaccine Immunology
- Meningococcal Disease: The Organism, Clinical Presentation, and Worldwide Epidemiology
- (2010) Jaffar A. Al‐Tawfiq et al. JOURNAL OF TRAVEL MEDICINE
- Advances in the Development of Vaccines againstNeisseria meningitidis
- (2010) Lionel K.K. Tan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Quadrivalent meningococcal conjugate vaccines
- (2009) David Pace et al. VACCINE
- Meningococcal C conjugate vaccine: The experience in England and Wales
- (2009) Helen Campbell et al. VACCINE
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
- A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
- (2009) M. Knuf et al. VACCINE
- Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age
- (2009) S. Black et al. VACCINE
- Meningococcal polysaccharide vaccines: A review
- (2008) Varsha S. Joshi et al. CARBOHYDRATE POLYMERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started